Immunological reactivity of P. I. Klimuk and V. I. Sevastyanov was studied before and after their 63-day flight aboard the orbital station Salyut-4. The study used the methods to assay reactivity of T- and B-lymphocytes (PHA-blast-transformation, nonspecific formation of rosettes with sheep red blood cells, immunofluorescence to identify cells carrying immunoglobulin receptors on their surface, serum level of immunoglobulins as a function of Becells). Sensitization of the human body to allergenes of representatives of normal automicroflora of Staphylococcus, Streptococcus, Proteus and E. coli was examined. Specific immunological reactivity which was marked on the 2nd day and tended to return to normal on the 7th day postflight as well as a significant decrease of IgA were noted. Postflight P. I. Klimuk showed sensitization to allergens of Staphylococcus and Streptococcus. Results of immunological examinations of the first and second expeditions aboard the orbital station Salyut-4 were compared.
Download full-text PDF |
Source |
---|
Front Immunol
January 2025
The Lautenberg Center for Immunology and Cancer Research, The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Alternative splicing (AS) is a mechanism that generates translational diversity within a genome. Equally important is the dynamic adaptability of the splicing machinery, which can give preference to one isoform over others encoded by a single gene. These isoform preferences change in response to the cell's state and function.
View Article and Find Full Text PDFFront Immunol
January 2025
Department of Pathology, Microbiology & Immunology, New York Medical College, Valhalla, NY, United States.
Rationale: Approximately 32 million people in the United States suffer from food allergies. Some food groups, such as legumes - peanuts, tree nuts, fish, and shellfish, have a high risk of cross-reactivity. However, the murine model of multiple food group cross-reactivity is limited.
View Article and Find Full Text PDFJ Allergy Clin Immunol Glob
February 2025
Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology, Cincinnati, Ohio.
Background: Omalizumab (OMA), a recombinant humanized IgG monoclonal anti-IgE antibody, is approved for treatment for chronic spontaneous urticaria (CSU) refractory to second-generation H-antihistamine (SGAH) therapy. However, currently, there are no validated serum biomarkers to reliably predict response to OMA treatment.
Objective: We explored the real-world clinical utility of using serum biomarkers for predicting response to OMA for CSU patients with disease refractory to high-dose SGAH therapy.
Oncoimmunology
December 2025
Université de Franche-Comté, EFS, INSERM, UMR RIGHT, Besançon, France.
Tissue-resident memory (T) T cells have emerged as key players in cancer immunosurveillance, and their presence has been linked to a favorable clinical outcome in solid cancer patients. Liver metastases exhibit a highly immunosuppressive tumor microenvironment, however, the role and clinical impact of T cell infiltration in colorectal cancer remain elusive. The expression of several tissue residency and activation biomarkers has been investigated on tumor-infiltrating lymphocytes isolated from 26 patients' colorectal cancer liver metastases (CRC liver metastases) and compared to 16 peripheral blood samples of patients with CRC liver metastases.
View Article and Find Full Text PDFAllergy Asthma Clin Immunol
January 2025
Division of Allergy & Immunology, Department of Medicine, Queen's University, Kingston, ON, Canada.
Drug allergy encompasses a spectrum of immunologically-mediated hypersensitivity reactions (HSRs) with varying mechanisms and clinical presentations. This type of adverse drug reaction (ADR) not only affects patient quality of life, but may also lead to delayed treatment, unnecessary investigations, and increased morbidity and mortality. Given the spectrum of symptoms associated with the condition, diagnosis can be challenging.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!